Article Details
Retrieved on: 2021-10-21 09:46:14
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
During the quarter, we continued to manufacture remdesivir for COVID-19, under a voluntary licensing agreement from Gilead.
Article found on: www.biospectrumindia.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here